View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 6, 2018

Ares Genetics to develop AI diagnostic test for infectious diseases

Ares Genetics, a division of molecular diagnostics company Curetis, has commenced the development of a new diagnostic test to detect microbial infections and predict responses to antimicrobial therapies.

Ares Genetics, a division of molecular diagnostics company Curetis, has commenced the development of a new diagnostic test to detect microbial infections and predict responses to antimicrobial therapies.

The new ARESupa Universal Pathogenome Assay will leverage Curetis’ ARES Technology Platform and genetic antimicrobial resistance database, called ARESdb, for interpreting results.

“The ARESupa diagnostic test aims to detect nearly all types of pathogens in a variety of samples. It is expected to use a single laboratory workflow to predict response to different antimicrobial drugs.”

The ARES Technology Platform is based on next-generation sequencing (NGS), while ARESdb is an artificial intelligence (AI) powered genetic pathogen reference database.

The ARESupa diagnostic test will be designed to detect nearly all types of pathogens in a variety of samples. The test is also expected to be able to use a single laboratory workflow to predict response to different antimicrobial drugs.

It will be initially offered as a laboratory test, with plans to obtain regulatory approvals for use as an in-vitro diagnostic (IVD) and subsequent commercialisation.

Currently, Ares Genetics is building a research and development (R&D) and diagnostic service lab at the Vienna BioCenter Campus in Vienna, Austria.

The facility will focus on supporting the in-house development and initial launch of the new diagnostic test as a laboratory-developed product in Europe.

Ares Genetics is also considering certain fast-track options to roll out the laboratory-developed version of ARESupa in the US. This launch will carried out only after completing development of first-generation of the test.

Ares Genetics managing director Achim Plum said: “With ARESupa, we intend to take molecular testing for microbial infections to the next level, leveraging the anticipated adoption of NGS technology in clinical diagnostics.”

Ares Genetics and Curetis have entered into an agreement with China-based firm MGI to create an integrated and fully automated platform for analysing different types of human samples for microbial infections using NGS.

Also, the company is in talks with other NGS technology providers to leverage their solutions for deploying ARESupa.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network